Taxus Cardium Pharmaceuticals Group Inc. (Taxus Cardium) is a regenerative medicine biotechnology company. The Company is focused on the development of advanced regenerative therapeutics designed to promote the activation and growth of microvascular circulation to enhance perfusion of ischemic cardiac tissue as a potential treatment for heart disease; and granulation tissue as a treatment for chronic non-healing wounds. Its product Generx (alferminogene tadenovec) is an adenovector (serotype 5) Deoxyribonucleic acid (DNA) based gene therapy construct that encodes the Fibroblast Growth Factor-4 (FGF-4) gene. Its product Excellagen is a pharmaceutically formulated acellular biological modulator that is engineered to activate and promote wound healing. The Company's subsidiaries include Angionetics Inc., Activation Therapeutics, Inc. and LifeAgain Insurance Solutions, Inc, among others.